Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.

Share:
Related LLY
Analyst: Here's Why Eli Lilly Is Worth More Than It Used To Be
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
Sanofi plans to launch new long-acting insulin in U.S. on Monday (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Eli Lilly & Co. closed on Tuesday at $52.80.

Latest Ratings for LLY

DateFirmActionFromTo
Mar 2015SunTrust Robinson HumphreyMaintainsBuy
Mar 2015Leerink SwannMaintainsOutperform
Feb 2015JefferiesMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...